FDA Approves Omisirge: New Allogeneic Stem Cell Therapy for Hematologic Cancers

The U.S. Food and Drug Administration (FDA) has granted **FDA omisirge approval** to Omisirge (omidubicel-onlv), an allogeneic hematopoietic stem cell transplantation product. This approval marks a significant advancement in treating hematologic malignancies, offering a new option for patients undergoing stem cell transplantation. The cellular therapy is intended to improve engraftment and immune reconstitution, particularly in individuals lacking matched donors.

Drug Overview

Omisirge (omidubicel-onlv) is a cellular therapy product derived from umbilical cord blood. It is indicated for use in allogeneic hematopoietic stem cell transplantation (HSCT) to treat hematologic malignancies such as leukemia and lymphoma. The mechanism of action involves ex vivo expansion of CD34+ hematopoietic stem and progenitor cells from umbilical cord blood using nicotinamide-based culture technology to increase cell dose and improve engraftment kinetics.

Clinical Insights

Omisirge's efficacy was demonstrated in a Phase III clinical trial. The primary endpoint was time to neutrophil engraftment and incidence of graft failure. Key efficacy data showed faster neutrophil and platelet recovery compared to standard cord blood transplantation. The safety profile of omidubicel-onlv is consistent with adverse events typical of allogeneic HSCT, including graft-versus-host disease (GVHD), infections due to immunosuppression, and cytopenias. No unexpected toxicities were reported in clinical trials.

Regulatory Context

The approval pathway for omidubicel involved an Investigational New Drug (IND) application, followed by Phase 1/2 safety and efficacy trials, and a pivotal Phase 3 study. The FDA review included evaluation under the biologics license application (BLA) process, with considerations for cellular and gene therapy product regulations.

Market Impact

Omisirge offers a novel alternative to traditional bone marrow and peripheral blood stem cell transplants, especially for patients without matched donors. The target population includes patients undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies such as leukemia and lymphoma, particularly those lacking matched sibling or unrelated donors. It differentiates itself by using nicotinamide-based ex vivo expansion of cord blood CD34+ cells to increase cell dose and improve engraftment kinetics, offering faster hematopoietic recovery compared to standard cord blood transplantation. Competitive drugs include bone marrow stem cells, peripheral blood stem cells, and other cord blood-derived products.

Future Outlook

Further studies may explore label expansions and combination trials to broaden the applicability of Omisirge in different patient populations and treatment settings.

Frequently Asked Questions

References

References

1. U.S. Food and Drug Administration. FDA approval. Accessed 2026-04-03.